The modern world of pharmaceutical treatments would be unthinkable without vaccines. It is a well-known truth that prevention is cheaper than treatment, and the whole vaccine business is a living example of that this may mean in real life. In fact, vaccines have helped prevent or even eradicate a number of serious diseases and this is an ongoing trend continuing in our modern world. New and promising vaccines are in development that may remove some of the human race’s biggest fears in life.
Vaccines have revolutionized therapeutic treatment, but to truly eradicate diseases, vaccines must be available and affordable everywhere. Our modular engineering concept is designed to facilitate such Vaccines.
Today, the vaccine industry addresses a wealth of diseases, ranging from measles and flu through tropic diseases and pediatric vaccination programs to cervical cancer, and is the fastest growing segment in the pharmaceutical industry.
Bulk vaccine manufacturing is subject to many challenges and rapid development unique to vaccines.
The production of bulk vaccines involves challenges and issues that are not often seen in other pharmaceuticals production, such as egg-based processes, containment and biosafety, and downstream processes that are almost exclusive to vaccine production.
Vaccine production is more than 100 years old and a well-established technology. An additional trend is that non-injeactable vaccines (e.g. tables and inhalers) are emerging as a convenient and efficient way of dealing with some diseases, in particular allergies.
Integrated Project Services (IPS) has been involved in all of these areas working for a great number of the leading vaccine producers worldwide. Our team includes leading vaccine experts with many years of industry experience.
We can help you establish all the relevant process and utilities for cost effective global bulk vaccine manufacturing whether it is for a full facility, an upgrade or an expansion including fast track projects and multi products facilities, process development and scale up or process troubleshooting. We also develop modular vaccine facilities based on vaccine biotypes.